Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.23 USD | -0.62% | -1.56% | -23.76% |
Sales 2024 * | - | Sales 2025 * | 25.86M 35.31M | Capitalization | 83.21M 114M |
---|---|---|---|---|---|
Net income 2024 * | -69M -94.19M | Net income 2025 * | -69M -94.19M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.22 x |
P/E ratio 2024 * |
-1.44
x | P/E ratio 2025 * |
-2.18
x | Employees | 54 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84% |
Latest transcript on Leap Therapeutics, Inc.
1 day | -0.46% | ||
1 week | -1.56% | ||
Current month | +18.80% | ||
1 month | +14.91% | ||
3 months | +17.91% | ||
6 months | +114.97% | ||
Current year | -23.76% |
Managers | Title | Age | Since |
---|---|---|---|
Doug Onsi
CEO | Chief Executive Officer | 55 | 10-12-31 |
Chris Mirabelli
CHM | Chairman | 69 | 10-12-31 |
Jason Baum
CTO | Chief Tech/Sci/R&D Officer | 45 | 20-08-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Loscalzo
BRD | Director/Board Member | 72 | 15-12-31 |
Nissim Mashiach
BRD | Director/Board Member | 63 | 16-12-31 |
Chris Mirabelli
CHM | Chairman | 69 | 10-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 3.16 | -2.77% | 33 923 |
24-04-26 | 3.25 | +2.52% | 403,202 |
24-04-25 | 3.17 | -3.65% | 213,233 |
24-04-24 | 3.29 | +2.81% | 200,614 |
24-04-23 | 3.2 | -0.31% | 89,131 |
Delayed Quote Nasdaq, April 29, 2024 at 11:04 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.76% | 83.21M | |
-2.63% | 103B | |
+1.67% | 95.28B | |
+1.75% | 22.15B | |
-15.31% | 21.02B | |
-8.58% | 18.15B | |
-41.01% | 16.73B | |
-13.27% | 16.05B | |
+4.02% | 13.68B | |
+34.74% | 12.17B |
- Stock Market
- Equities
- LPTX Stock